Among HER2-positive breast cancer patients, 292 cases (68.2%) achieved PR, 19 cases (4.4%) achieved CR, and only 4 cases (0.9%) exhibited PD following NAT. The gene discussed is ERBB2; the disease is breast carcinoma.